

INTERNATIONAL WORKSHOP ON  
**HIV PEDIATRICS** 2020



VIRTUAL WORKSHOP | 16 - 17 NOVEMBER



**Program book**

# Table of Contents

<b>Welcome</b>	<b>3</b>
<b>Objectives</b>	<b>5</b>
<b>Practical Information</b>	<b>6</b>
<b>Accreditation</b>	<b>7</b>
<b>Organizing Committee</b>	<b>8</b>
<b>Scientific Committee</b>	<b>9</b>
<b>Program</b>	<b>10</b>
<b>On Demand</b>	<b>18</b>
<b>Faculty</b>	<b>19</b>
<b>Acknowledgments</b>	<b>36</b>



# Welcome

Dear Colleagues,

We are happy to welcome you to the **12th International Workshop on HIV Pediatrics 2020!**

Given the emergence of SARS-CoV-2 as a global pandemic, the Workshop is being held virtually for the first time. This virtual platform will enable delegates from around the world to come together, connecting virtually, to advance the science and effectiveness of programs related to HIV in infants, children, adolescents, pregnant and breastfeeding women, and families.

The Workshop will showcase the latest developments in pediatric and maternal HIV research in an innovative and interactive global platform and in variety of formats that will be accessible throughout the meeting, including:

- Plenary talks that cover a range of topics from the latest UNAIDS data on pediatric HIV, the intersection of pediatric HIV with the COVID-19 pandemic, advances in HIV cure research across the lifespan, perspectives on HIV disclosure from the North and South, and the latest data on PrEP in pregnancy and breastfeeding and global gaps and potential solutions in prevention of mother to child HIV transmission.
- A special session focused on critical issues related to COVID-19 in pediatrics, including a talk from Dr. Anthony Fauci providing an update on SARS-CoV-2 vaccines.
- Clinical case presentations with international panel of discussants.
- Concurrent oral abstract sessions that will highlight the latest advances in pediatric and adolescent HIV treatment and care, insights into effective program roll-out and prevention of mother to child transmission, and the effects of COVID-19 on pediatric and adolescent HIV programs.



# Welcome

- Four concurrent “poster walk” sessions highlighting the top posters from young investigators moderated by experts in pediatric HIV research.
- Over 50 posters on the latest in pediatric, adolescent and maternal HIV research with short video presentations.
- A special adolescent panel of youth from around the world discussing life “growing up with HIV” moderated by Dr. Caroline Foster from Imperial College in London.
- A “Young Investigator Meet the Faculty” breakfast session to allow dialogue of young investigators with members of the Pediatric Workshop Scientific Committee.

We hope that you, your loved ones, and your colleagues and co-workers are staying safe and sheltering as best you can from the pandemic.

We are excited to have you join us to share the latest advances in clinical and prevention research in pediatric HIV and it’s intersection of the COVID-19 pandemic in this new virtual format.

On behalf of the Organizing Committee,

*Lynne Mofenson  
Elaine Abrams  
Ann Petru  
Ted Ruel  
HIV Pediatrics Workshop Team*



# Objectives

## Meeting objectives

The meeting aims at:

- Providing updates on the latest research on new pediatric antiretroviral drugs, treatment and cure strategies in children and adolescents.
- Understanding of available prevention technologies and their application for prevention of HIV in adolescents in high and low resource settings.
- Sharing results from implementation science research on how to optimally implement proven interventions for prevention of perinatal HIV transmission and pediatric care and treatment in developing countries.
- Understanding risks for HIV transmission to pregnant and lactating women and implications for the fetus/infants.
- Evaluating effectiveness of and gaps in programs for prevention of mother-to-child HIV transmission and interventions to improve such programs.
- Understanding the intersection between the COVID-19 pandemic and pediatric HIV programs, and what is known about SARS-CoV-2 infection in children.
- Understanding coinfections, complications and comorbidities of long-term HIV infection and its therapy, to enable improved management of HIV in children.
- Enhancing communication and encouraging new collaborations between junior and senior investigators, north and south, and academia, governmental public health agencies, and industry to promote both research in pediatric HIV and successful translation of such research into advances in prevention and treatment of HIV in children, youth, and families.
- Disseminating knowledge and data exchanged by workshop participants beyond the audience of the live event through posting of all presentations on the meeting website, thus maximizing the impact of the meeting by reaching the whole HIV research community.
- To support junior investigators to study priority questions in HIV prevention and treatment during pregnancy, childhood and adolescence

## Learning objectives

After participating in this activity, the participants will:

- Describe the changing epidemiology of the HIV pediatric epidemic world-wide and new ways to better assess the impact of our interventions.
- Describe the impact of the COVID-19 pandemic on pediatric and maternal HIV programs, what is understood and remains to be learned about SARS-CoV-2 infection in children, and COVID-19 vaccine development
- Summarize optimal treatment and management strategies of HIV infection in infants, children, and adolescents and advances in cure research in relation to pediatric HIV.
- Describe innovations in pediatric case finding and linkage to treatment and care and issues related to pediatric HIV disclosure.
- Summarize remaining gaps in global prevention of mother-to-child HIV transmission and potential interventions.
- Describe the management of complex coinfections/comorbidities in HIV-infected children, such as tuberculosis, and manifestations of SARS-CoV-2 infection in children.
- Describe the special issues related to HIV infection in adolescents and young people, and HIV prevention and programming options for youth.



# Practical Information

## Abstracts

Accepted abstracts are published in **Reviews in Antiviral Therapy & Infectious Diseases, Volume 2020\_9**.

You can download the abstract book [here](#).

## Certificate of Attendance

Certificates of attendance will be sent by e-mail after completion of the feedback forms.

## Feedback

Your feedback is very valuable to us and enables us to further improve this workshop. After each session a short questionnaire will pop-up and we would like to ask you to take a minute to complete it. After the workshop, a survey will be send to you via email, with other questions to improve this workshop.

## Group Picture

We ask you all to take a photo of yourself watching the workshop and send it to the workshop secretariat at [rikke@vironet.com](mailto:rikke@vironet.com) or [karin@vironet.com](mailto:karin@vironet.com). They will stitch it all together and send out the finished virtual group photo at the end of the workshop.

## Networking

Feel free to connect with your fellow delegates both via the chats and the discussion forums.

## Presentations and Webcasts



Webcasts of the presentations along with the PDF presentations will be available on

[www.AcademicMedicalEducation.com](http://www.AcademicMedicalEducation.com)

3 weeks after the meeting. You will be able to watch the presentations on the

workshop portal until 3 weeks after the workshop:

<https://www.hivpediatrics2020.com/>.

## Poster Gallery & Poster Viewing

During the virtual workshop all accepted posters are displayed in the Poster Gallery. The Poster Gallery is always open for you.

During the Virtual Tea Break at 12.35 PM on Monday and the Virtual Tea Break at 12.40 PM on Tuesday you can visit the posters and interact with the presenters - just like if it was a face-to-face workshop.

Please make sure to make use of this opportunity and learn more about their interesting findings.

## Social Media

We encourage you to post news about **#HIVPED** to your social media accounts and tweet about **#HIVPED** as often as you like during the workshop. You can either post your own tweet to your followers using the hashtag **#HIVPED** or retweet a message through the official **@Virology\_Edu** account.

## Time Zones

Times are in Eastern Standard. If you need to convert the times to your timezone, this website might be of interest to you:

<https://www.worldtimebuddy.com/>

## Our Team



**Karin Siebelt**

**Team Leader**

[karin@vironet.com](mailto:karin@vironet.com)



**Rikke Rode**

**Project Coordinator**

[rikke@vironet.com](mailto:rikke@vironet.com)



**Lara da Silva Miguel**

**Project Coordinator**

Disclaimer: This workshop aims to offer participants the opportunity to share information. The Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaim all liability for injuries or losses of whatever nature incurred by individuals attending the conference.



# Accreditation

## Accreditation

The International Workshop on HIV Pediatrics 2020, Utrecht (live streaming), Netherlands, 16/11/2020-17/11/2020 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 6 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20.

In order to help you issue individual certificates to each participants, please find below the breakdown of ECMEC®s per day:

16.11.2020 - 3.00

17.11.2020 - 3.00

The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.



# Organizing Committee



**Elaine Abrams**  
**MD**  
ICAP Mailman School of Public Health, Columbia University, United States



**Lynne Mofenson**  
**MD**  
Elizabeth Glaser Pediatric AIDS Foundation, United States



**Ann Petru**  
**MD**  
UCSF-Benioff Children's Hospital Oakland, United States



**Ted Ruel**  
**MD**  
UCSF-Benioff Children's Hospital San Francisco, United States



**Charles Boucher**  
**MD, PhD**  
Erasmus Medical Center, The Netherlands



**Mark Cotton**  
**MD, PhD**  
Stellenbosch University, South Africa



**Patricia Flynn**  
**MD**  
St Jude Children's Research Hospital, United States



**Carlo Giaquinto**  
**MD**  
University of Padova, Italy



**Thanyawee Puthanakit**  
**MD**  
Chulalongkorn University, Thailand



**Nadia Sam-Agudu**  
**MD, CTROPED**  
Institute of Human Virology, Nigeria



**Gareth Tudor-Williams**  
**MD**  
Imperial College London, United Kingdom





# Scientific Committee

**Moherndran Archary, MBChB, PhD** – University of KwaZulu Natal, South Africa

**Jason Brophy, MD** – Children’s Hospital of Eastern Ontario, Canada

**Tsungai Chipato, MBChB** – University of Zimbabwe College of Health Sciences, Zimbabwe

**Polly Clayden** – HIV i-Base, United Kingdom

**Anita De Rossi, PhD** – AIDS Reference Center, Italy

**Marinella Della Negra, MD** – Hospital Emilio Ribas, Brazil

**Brian Eley, MD** – Red Cross Children’s Hospital, South Africa

**Albert Faye, PhD** – Denis Diderot University, France

**Rashida Ferrand, MBBS, MRCP, MSc, DRM&H** – London School of Hygiene & Tropical Medicine, United Kingdom

**Tessa Goetghebuer, MD** – Hôpital St Pierre, Belgium

**Ellen Chadwick, MD** – Childrens Memorial Hospital, United States

**Ali Judd, PhD** – University College London, United Kingdom

**Valériane Leroy, MD** – Inserm, France

**Chewe Luo, MD, PhD** – UNICEF, USA

**Dorothy Mbori-Ngacha, MBChB, MMed, MPH** – United Nations Children’s Fund, South Africa

**Philippa Musoke, MD** – Makerere University & Johns Hopkins University Research Collaboration, Uganda

**Sharon Nachman, MD** – SUNY Health Science Center Stony Brook, United States

**Paul Palumbo, MD** – Dartmouth-Hitchcock Medical Center, United States

**Martina Penazzato, MD, MSc, PhD** – WHO, Switzerland

**Jorge Pinto, MD, DSc** – Federal University of Minas Gerais, Brasil

**Natella Rakhmanina, MD, PhD, FAAP, AAHIV** – Children’s National Hospital / George Washington University, United States

**George Siberry, MD, MPH** – USAID, United States

**Lynda Stranix-Chibanda, MBChB, MMed** – University of Zimbabwe, Zimbabwe

**Tavitiya Sudjaritruk, MD, ScM, PhD** – Chiang Mai University, Thailand

**Graham Taylor, MD** – Imperial College London, United Kingdom

**Claire Thorne, BA, MSc, PhD** – University College London, United Kingdom

**Marissa Vicari, MA** – International AIDS Society, Switzerland

**Rachel Vreeman, MD, MS** – Icahn School of Medicine at Mount Sinai, United States



# Program

## MONDAY 16 NOVEMBER

*Times are in Eastern Standard Time (EST)*

### Opening

- 10:00 AM **Opening Words**  
**Lynne Mofenson, MD**  
Elizabeth Glaser Pediatric AIDS Foundation, United States  
**Elaine Abrams, MD**  
ICAP at Columbia University, United States
- 10:05 AM **Opening Co-Chairs**  
**Ted Ruel, MD**  
UCSF-Benioff Children's Hospital San Francisco, United States  
**Ann Petru, MD**  
UCSF-Benioff Children's Hospital Oakland, United States

### Session 1 Global Update

*Chair: Thanyawee Puthanakit*

- 10:10 AM **The HIV Epidemic in Infants, Children, Adolescents and Women Today – 2020 UNAIDS Update**  
**Mary Mahy, ScD, MHSc**  
UNAIDS, Switzerland
- 10:22 AM **HIV and COVID-19 in Children, Double Trouble**  
**Martina Penazzato, MD, MSC, PhD**  
WHO, Switzerland
- 10:39 AM **Advances in Cure Research Across the Lifespan**  
**Dan Kuritzkes, MD**  
Harvard Medical School / Brigham and Women's Hospital, United States
- 10:55 AM **Q & A**

11:20 AM Tea Break

### Session 2 Oral Abstracts Presentations - Simultaneous

*Chairs: Ellen Chadwick & Jorge Pinto*

1. Pediatric HIV Treatment – Old drugs, New Drugs

2. Diagnosis, Case-Finding, Retention and Viral Suppression in Children Living With HIV



## 11:35 AM Abstract Session 1: Pediatric HIV Treatment – Old drugs, New Drugs

Chair: Ellen Chadwick

- |  |                                  |
|--|----------------------------------|
| Twenty-Four Week Safety, Tolerability and Efficacy of Dolutegravir Dispersible Tablets in Children 4 Weeks to <6 Years Old with HIV: Results from IMPAACT P1093  | #1 Theodore Ruel, United States  |
| Pediatric Dolutegravir (DTG) Dosing Recommendations Derived from Combined P1093 and ODYSSEY Population Pharmacokinetic Analysis                                  | #2 Rajendra Singh, United States |
| Safety, Pharmacokinetics, and Efficacy of Low-Dose E/C/F/TAF in Virologically Suppressed Children ≥2 Years Old Living with HIV                                   | #3 Eva Natukunda, United States  |
| Safety, Pharmacokinetics And Acceptability Of The Abc/3tc/Lpv/R Granules (4-In-1) In Children Living With HIV (3-20kg) In Uganda: LOLIPOP Study                  | #4 Juliet Mwangi, Uganda         |
| The “Dtgs” of DTG for Children and Adolescents Living with HIV (CALHIV): Descriptions, Trends, and Gaps of Rolling Out Dolutegravir in CALHIV In Mbeya, Tanzania | #5 Jason Bacha, Tanzania         |
| Acceptability of a New 4-In-1 Abacavir/Lamivudine/Lopinavir/Ritonavir Paediatric Fixed-Dose Combination: The Caregiver-Child Dyads’ Perspective                  | #6 Ogara Collin, Uganda          |

12:19 PM **Q & A**

## 11:35 AM Abstract Session 2: Diagnosis, Case-Finding, Retention and Viral Suppression in Children living with HIV

Chair: Jorge Pinto

- |   |                                       |
|---|---------------------------------------|
| A Validated Outpatient Department HIV Screening Tool for Children 18 Months To 14 Years as Efficient as Index Testing in Uganda   | #7 Rhoderick Machekano, United States |
| Point of Care Samba-Ii Vs Centralized Laboratory Viral Load Assays Among HIV-1 Infected Children, Adolescents and Young Adults in Rural Zimbabwe: A Randomized Controlled Trial | #8 Vinie Kouamou, Zimbabwe            |
| “Right Under Our Nose”: A Simple Screening Tool to Identify HIV-Positive Children Outside of the PMTCT Program at Outpatient Departments in Malawi                              | #9 Anna Tallmadge, Malawi             |
| Finding the Remaining Unidentified Children Living with HIV: Opportunities Through Index Testing  | #10 Megan Gleason, United States      |
| Factors Associated with Late Presentation of HIV-Infected Infants for Early Infant HIV Diagnosis (Eid) Services in Kenya  | #11 Agnes Langat, Kenya               |

12:11 PM **Q & A**

12:35 PM Virtual Break & Poster Discussions



## Session 3 Clinical Case Presentations

*Chair: Natella Rakhmanina*

1:05 PM **Clinical Case Presentation 1**  
**Vanessa Rouzier, MD**  
GHESKIO Centers, Haiti / Weill Cornell Center for Global Health, United States

### Commenters

**Nadia Sam-Agudu, MD, CTROPMED**

Institute of Human Virology, Nigeria

**Thanyawee Puthanakit, MD**

Chulalongkorn University, Thailand

**Sharon Nachman, MD**

SUNY Stony Brook, United States

1:25 PM **Clinical Case Presentation 2**  
**Elizabeth Whittaker, PhD, DTM&H, MRCPCH**  
Imperial College London, United Kingdom

### Commenters

**Nadia Sam-Agudu, MD, CTROPMED**

Institute of Human Virology, Nigeria

**Thanyawee Puthanakit, MD**

Chulalongkorn University, Thailand

**Sharon Nachman, MD**

SUNY Stony Brook, United States

1:45 PM Tea Break

## Session 4 Undetectable = Untransmittable – Relevance to Breastfeeding

*Chair: Nadia Sam-Agudu*

2:00 PM **Is U=U Applicable to Breastfeeding?**  
**Lynne Mofenson, MD**  
Elizabeth Glaser Pediatric AIDS Foundation, United States

2:20 PM **Panel Discussion**  
**Lucy Wanjiku Njenga**  
Positive Young Women Voices, Kenya  
**Fungai Murau**  
Independent Consultant, United Kingdom  
**Brittany Cameron**  
Canadian Positive People Network, Canada

2:40 PM Tea Break



## Parallel Guided Poster Tours

1. Pediatrics HIV Diagnosis and Treatment
2. Adolescents and HIV
3. Prevention of Mother-to-Child HIV Transmission
4. Pediatrics HIV Care and Monitoring

### 2:50 PM Guided Poster Tour 1: Pediatrics HIV Diagnosis and Treatment

*Moderator: Mark Cotton*

Trends in Pediatric Antiretroviral Treatment in U.S. President's Emergency Plan for AIDS Relief-Supported Countries in Sub-Saharan Africa —2016–2019	#30 Elizabeth Rabold, United States
Model Informed Prediction of Dolutegravir Pharmacokinetics in the Neonates	#31 Hardik Chandasana, United States
Absence of Selection for Integrase Inhibitor Resistance via the Q148H Pathway in HIV-1 Subtype F Integrases: Evaluation of Treatment Outcomes, Replicative Capacity, and Drug Resistance	#32 Mijael Rozenszajn, Argentina
Expanded Index Testing and Community-Based Testing Modalities in Nigeria Are Effective in Identifying Children Living with HIV	#33 Ariana Traub, United States
Evaluating the Performance of the Genexpert HIV-1 Qualitative Assay as a Consecutive Test for a New Early Infant Diagnosis Algorithm	#34 Aurélie Mukendi, South Africa

### 2:50 PM Guided Poster Tour 2: Adolescents and HIV

*Moderator: Patricia Flynn*

Change in Sexual Behavior and Partner Communication Following Oral HIV Self-Testing Among Adolescents and Young Adults in Kenya	#35 Matthew Driver, United States
High Rates of Primary and Secondary Syphilis Infections in HIV-Positive Adolescent and Young Adult Men Who Have Sex With Men in Atlanta, GA	#36 Leah Loerinc, United States
Overlapping Significant Life Events are Associated with HIV Viral Non-Suppression Among Youth in Clinics in Rural East Africa	#37 Florence Mwangwa, Uganda
Qualitative Analysis of a Mobile Whatsapp Group Messaging Intervention for Adolescents Living with HIV in Kenya	#38 Ashley Chory, United States
High Prevalence of Asymptomatic Sexually Transmitted Infections at Baseline Clinic Visit Following HIV Diagnosis in Atlanta Youth	#39 Amy Scheel, United States



# Program

## 2:50 PM Guided poster tour 3: Prevention of Mother-to-Child HIV Transmission

Moderator: Lynda Stranix-Chibanda

Cascades of Care for Preventing Vertical HIV Transmission in Canada	#40 Shu Nan Jessica Li, Canada
Opportunity Analysis for HIV Risk and Acquisition Among Pregnant Adolescent Girls and Young Women in Antenatal Care Services in Ten African Countries	#41 Cosima Lenz, United States
Continuous Quality Improvement Improves Retention of Clients in Prevention of Mother-To-Child Transmission of HIV Program (Wakiso District, Uganda)	#42 Grace Margaret Naikazi, Uganda
Higher Prevalence of Stunting and Lower Length, Weight, and Head Circumference among HIV-Exposed Uninfected Infants	#43 Jillian Neary, United States
Adoption of WHO's HIV Retesting Policy for HIV-Negative Women During the Breastfeeding Period in 10 High HIV-Burden African Countries	#44 Barbara Burmen, South Africa

## 2:50 PM Guided poster tour 4: Pediatrics HIV Care and Monitoring

Moderator: George Siberry

The Changing Face of Paediatric HIV: A Review of the Evolving Clinical Characteristics of a Paediatric and Adolescent Patients at a Clinic in Johannesburg, South Africa	#45 Josephine Keal, South Africa
Cognitive Outcomes at 7 and 9 Years After the Children with HIV Early Antiretroviral (CHER) Trial	#46 Kaylee van Wyhe, South Africa
Retention and viral suppression among child -caregiver pairs enrolled in family centered differentiated model of care in Kenya, 2019	#63 Immaculate Mutisya, Kenya
Low Access To Viral Load Monitoring And Poor Virological Outcomes In Children And Adolescents Living With HIV In West Africa	#48 Désiré Lucien Dahourou, Burkina Faso
Time to Repeat Viral Load Testing Following an Unsuppressed Viral Load Among Adolescents and Young Adults in Kenya	#49 Cyrus Mugo, Kenya
Clinical Outcomes of Infants Identified HIV-Positive at Birth Through Routine Point-of-Care Early Infant HIV Diagnosis; A Pilot Program In Eswatini	#50 Philisiwe Ntombenhle Khumalo, Swaziland



## TUESDAY 17 NOVEMBER

09:00 AM Young investigator “Meet the faculty” - Nadia Sam-Agudu, Ted Ruel, Patricia Flynn, Carlo Giaquinto, Ali Judd, Elaine Abrams, Ann Petru and Lynne Mofenson - Sign up Required

### Session 5 Pediatrics Session

*Chair: Ted Ruel*

10:00 AM **The “Why, When and How To” of HIV Disclosure: Perspectives From the North and South**  
**Ann Petru, MD**

UCSF Benioff Children’s Hospital Oakland, United States

**Regina Oladokun, MD, MPH**

University of Ibadan, Nigeria

10:35 AM **PrEP in Pregnancy and Breastfeeding: the Why, What and How**

**Jillian Pintye, RN, MPH, PhD**

University Washington Seattle, United States

10:54 AM **Prevention of Mother To Child HIV Transmission - Global Gaps and Potential Solutions**

**Benjamin Chi, MD, MSc**

University of North Carolina, United States

11:10 AM **Q & A**

11:25 AM Tea Break

### Session 6 Oral Abstracts Presentations - Simultaneous

*Chairs: Moherdran Archary, Valérie Leroy, and Rachel Vreeman*

**3. Adolescents and HIV**

**4. COVID-19 in Children**

**5. Prevention of HIV Mother-to-Child Transmission**

### 11:40 AM Abstract Session 3: Adolescents and HIV

*Chair: Moherdran Archary*

Development and Validation of the HIV Adolescent Readiness for Transition Scale (HARTS)

#13 Brian Zaroni, United States

Point-of-Care Viral Load Testing Among Adolescents and Young Adults Living with HIV in Haiti: A Randomized Control Trial

#14 Lindsey Reif, United States

Antiretroviral Drug Transition and Adverse Event Monitoring among Adolescents 15 to 19 Years of Age in Kenya

#15 Maureen Syowai, Kenya

Bringing HIV and SRH Services Closer to Adolescents Girls and Young Women in Eswatini Through a Comprehensive Mobile HIV and SRH Package

#16 Sibongile Wusumani, Swaziland

Archived HIV-1 Drug-Resistance Variants in Cellular Reservoirs and its Determinants among Vertically-Infected Adolescents Failing Antiretroviral Therapy

#17 Joseph Fokam, Cameroon

Deficits Noted at 11 Years in Children with HIV Starting Early Antiretroviral Therapy in Fine Motor Dexterity and Auditory Working Memory

#18 Barbara Laughton, South Africa

12:22 PM **Q & A**



# Program

## 11:40 AM Abstract Session 4: COVID-19 in Children

Chair: Valériane Leroy

- |  |                                     |
|--|-------------------------------------|
| A Multi-Country Analysis of the Impact of COVID-19 on HIV Services for Children and Adolescents Living with HIV                                    | #19 Ariana Traub, United States     |
| Challenges of Remdesivir Pediatric Development for SARS-Cov-2 Infection in a Pandemic  | #20 Cheryl Pikora, United States    |
| A Multi-Country Analysis of the Impact of COVID-19 on Uptake of Multi-Month Dispensing for Children Living with HIV on Antiretroviral Therapy      | #21 Nimasha Fernando, United States |
| A Multi-Country Analysis of the Impact of COVID-19 on HIV Services for Pregnant and Breastfeeding Women and their Infants                          | #22 Alexandra Vrazo, United States  |
| Use of a Walk-In HIV and STI Testing Model for at Risk Youth Ages 13 to 24 - Assessment of the Impact of the COVID-19 Pandemic on Testing Services | #23 Isabella Lopez, United States   |

12:19 PM **Q & A**

## 11:40 AM Abstract Session 5: Prevention of HIV Mother-to-Child Transmission

Chair: Rachel Vreeman

- |  |   |
|--|---|
| Extent of In Utero Transfer of Tenofovir from Mother to Fetus: A Paired Analysis of Hair Specimens Collected at Birth from a Cohort in the United States | #24 Jillian Pintye, United States       |
| Children Who are HIV-Exposed and Uninfected Exhibit Immune Suppressive Plasma Biomarker Profiles   | #25 Alka Khaitan, United States         |
| Time to First Positive HIV-1 DNA PCR in Infants Infected with Subtype B HIV-1 is Delayed in the Presence of Maternal Antiretroviral Use                  | #26 Raji Balasubramanian, United States |
| Higher Hospitalization Rates in Children Born HIV-Exposed Uninfected in British Columbia, Canada, Between 1990 and 2012                                  | #27 Shu-Nan Jessica Li, Canada          |
| Longitudinal Evolution of Maternal Viral Loads During Pregnancy and Postpartum Among Women Living with HIV in South Africa                               | # 28 Faith Moyo, South Africa           |
| Maternal PrEP Use in HIV-Uninfected Pregnant Women in South Africa: Role of Stigma in PrEP Initiation and Persistence                                    | # 29 Alexander Moran, United States     |

12:28 PM **Q & A**

12:40 PM Tea Break & Poster Discussion





## Session 7 COVID-19 in Pediatrics

Chair: Elaine Abrams

- 1:10 PM **Susceptibility and Ability to Transmit**  
**Lynne Mofenson, MD**  
Elizabeth Glaser Pediatric AIDS Foundation, United States
- 1:27 PM **School/Daycare**  
**Moherndran Archary, MBChB, PhD**  
University of KwaZulu Natal, South Africa
- 1:42 PM **MTCT**  
**Daniele De Luca, MD, PhD**  
AP-HP Université Paris Saclay, France
- 2:01 PM **Clinical Illness Including MIS-C**  
**Elizabeth Whittaker, PhD, DTM&H, MRCPCH**  
Imperial College London, United Kingdom
- 2:20 PM **SARS-Cov-2 Vaccines**  
**Anthony Fauci, MD**  
Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health, United States
- 2:36 PM **Q & A**

## Closing

- 3:00 PM **Young Investigators Award**
- 3:05 PM **Closing Remarks**  
**Lynne Mofenson, MD**  
Elizabeth Glaser Pediatric AIDS Foundation, United States  
**Theodore Ruel, MD**  
UCSF-Benioff Children's Hospital San Francisco, United States  
**Ann Petru, MD**  
UCSF-Benioff Children's Hospital Oakland, United States  
**Elaine Abrams, MD**  
ICAP at Columbia University, United States



## ON DEMAND

### Youth Discussion Panel

Moderator: Dr. Caroline Foster

#### **Fletcher**

HIV/AIDS Rights Advocacy Association of Taiwan, Taiwan

#### **Sasha**

United Kingdom

#### **Joyce**

APYIN, Nigeria



*A short film created with young people who having grown up living with HIV. The film was written from the real stories and thoughts the young people shared, and performed by actors. The film explores issues including telling a sexual partner about your HIV, the challenges of medication adherence and social impacts HIV can bring to young people's lives.*



[https://www.youtube.com/watch?v=HHfW\\_uVzx8g](https://www.youtube.com/watch?v=HHfW_uVzx8g)



# Faculty

---



# Faculty



**SCIENTIFIC COMMITTEE/  
INVITED SPEAKER**

**MOHERNDRAN ARCHARY  
MBChB, PhD**

University of KwaZulu Natal,  
South Africa

Archary is a Paediatric Infectious Disease Specialist in the Department of Paediatrics and Child Health at King Edward VIII Hospital affiliated to the Nelson R Mandela School of Medicine, University of KwaZulu-Natal.

He is actively involved with the management of children with HIV both locally and nationally within South Africa.

His research interests include antiretroviral drug therapeutics, viral resistance and optimal timing of initiation of antiretroviral therapy in the developing world.

He serves on the COVID-19 Ministerial Advisory Committee (MAC), which provides the South African Government with evidence based advice to guide policy.

**Potential conflict of interest:**

No Potential conflict of interest



**WORKSHOP CHAIR**

**ELAINE ABRAMS  
MD**

ICAP Mailman School of  
Public Health,  
United States

Elaine Abrams is a Professor of Epidemiology and Pediatrics at Columbia University with over 35 years of experience in the prevention and treatment of HIV infection and associated infectious diseases in pregnant women, children, and their families. As the Senior Director for Research at ICAP, she leads ICAP's large research agenda and is responsible for the development of technical assistance and service programs for pediatric and perinatal prevention initiatives for ICAP programs in sub-Saharan Africa and Asia.

Dr. Abrams served three consecutive terms as Chair of the NIH-funded IMPAACT network HIV treatment scientific committee and currently guides the network scientific agenda as a member of the Senior Leadership Group. She chaired the WHO consolidated guidelines for the use of antiretroviral drugs since 2015, introducing universal treatment, antiretrovirals for prevention and optimized antiretroviral regimens with dolutegravir. She is also co-chair of the WHO Pediatric Antiretroviral Working Group and is actively involved in the development of policies and protocols for the study of antiretrovirals in children, adolescents, and pregnant and lactating women.

Dr. Abrams' research interests have focused on maternal-child health, mother-to-child HIV transmission, the natural history of pediatric HIV, and optimizing therapies for infants, children, adolescents and pregnant women and breastfeeding women.

**Potential conflict of interest:**

No Potential conflict of interest





## ORGANIZING COMMITTEE

**CHARLES BOUCHER**  
**MD, PhD**

Erasmus Medical Center,  
The Netherlands

Charles Boucher received his MD cum laude at the Academic Medical Center in 1987. In 1993 he finished his PhD in Virology at the University of Amsterdam. He published over 300 peer reviewed papers, that have appeared in Science, New England Journal of Medicine, The Lancet, Nature Medicine, Journal of Infectious Diseases and AIDS.

He coordinated several success European funded programs. He is the coordinator of a large network (33 countries) in Europe that studies the transmission of drug resistant HIV and chairs the European Society for Antiviral Research (ESAR). Prof. Boucher is an organizer of international workshops, meetings and conferences, a consultant throughout Europe and the United States, a reviewer for scientific journals and co-chairman of several international committees.

His current position is professor in Virology at the Erasmus Medical Center in Rotterdam, clinical microbiologist at the Erasmus Medical Center, coordinator of the Querido Honours College within the medical curriculum and Scientific Director at Virology Education, Utrecht, Netherlands.

### Potential conflict of interest:

No Potential conflict of interest



## INVITED SPEAKER

**BRITTANY CAMERON**

Canadian Positive People  
Network, Canada

Brittany Cameron is a 35-year-old woman from Canada who was diagnosed with HIV at 36 weeks pregnant with her first child in March of 2006; at that time was told she would not be able to breastfeed. She went on to have two more children, teaching her OBGYN PMTCT guidelines.

Living in a small town she experienced shame and stigma in her lack of ability to breastfeed especially given societal narratives that breast is best. She also experienced challenges in accessing science based information surrounding the complex issues that impact Positive Women in relation to breastfeeding and she has been advocating ever since.

Brittany wears many hats in the HIV sector; she is the current Co-Chair of the Canadian Positive People Network (CPPN), part of the Canadian #UequalsU Steering Committee, and works at her local ASO as the Peer Engagement Coordinator. In addition to her lived experience of HIV she has an educational background in Social Service Work; bringing to the work a deep sense of connection and willingness to meaningfully engage, enable and empower Women living with HIV to find their passion and become active agents of change in their lives and the lives of others.

### Potential conflict of interest:

No Potential conflict of interest



# Faculty



## SCIENTIFIC COMMITTEE

**ELLEN CHADWICK  
MD**

Childrens Memorial Hospital,  
United States

Ellen Gould Chadwick is Susan B. DePree Founders' Board Professor in Pediatric Adolescent and Maternal HIV Infection at Northwestern University's Feinberg School of Medicine and Director of the Section of Pediatric, Adolescent and Maternal HIV infection at the Ann & Robert H. Lurie Children's Hospital of Chicago. She has been engaged in research in the field of Pediatric HIV since participating in the first NIH-sponsored trial of the use of IVIG in children living with HIV in 1987.

Her primary work has been in leading Phase I/II trials of antiretroviral therapies in newborns and children under the age of 3 years, and very early treatment to achieve HIV remission as part of the IMPAACT Network, and longitudinal observational studies in children and youth living with HIV and uninfected children perinatally-exposed to HIV through the Pediatric HIV/AIDS Cohort Study.

She has been fortunate to work with collaborators and investigators from all over the world, and has benefitted from witnessing remarkable progress in the field of Pediatric HIV over the course of her career.

**Potential conflict of interest:**  
No Potential conflict of interest



## INVITED SPEAKER

**BEN CHI  
MD, MSc**

University of North Carolina,  
United States

Benjamin Chi is Professor of Obstetrics and Gynecology at the University of North Carolina at Chapel Hill. He lived in Lusaka, Zambia from 2003 to 2015, where he developed an extensive research portfolio focused on the prevention of mother-to-child transmission (PMTCT), HIV care and treatment, and maternal and child health.

Dr. Chi has served as PI for numerous grants funded by the National Institutes of Health, Centers for Disease Control and Prevention, Doris Duke Charitable Foundation, and Elizabeth Glaser Pediatric AIDS Foundation. He remains actively engaged in initiatives in Malawi, South Africa, Uganda, Zambia, and Zimbabwe. Alongside this research, he leads training programs designed to foster U.S. collaborations abroad, including several funded by the National Institutes of Health. Recently,

Dr. Chi served as technical lead for UNICEF's Last Mile to EMTCT operational guidance, which provides a framework to national programs seeking to identify and address programmatic gaps in PMTCT.

**Potential conflict of interest:**  
No Potential conflict of interest





## ORGANIZING COMMITTEE

**MARK COTTON**  
**MD, PhD**

Stellenbosch University /  
Tygerberg Children's Hospital,  
South Africa

Mark Cotton is Head of Division of Paediatric Infectious Diseases and Director of the Family Infectious Diseases Clinical Research Unit at Tygerberg Children's Hospital (TCH), Stellenbosch University (SU). He undertook a fellowship in paediatric infectious diseases at University of Colorado between 1991 and 1995.

He is affiliated to the IMPAACT and PENTA networks and has provided technical support for WHO initiatives since 2004 on the HIV Classification for HIV, antiretroviral guidelines and TB-HIV co-infection. He was co-PI and investigator in several clinical trials in children, both on ART strategy (CHER) and isoniazid prophylaxis and also ARV pharmacokinetics in HIV-infected children.

He is the principal investigator for the SU Clinical Trial Unit (SUN-CTU) with special focus on tuberculosis and HIV. He is involved in vaccine studies for TB and RSV and is including a recombinant BCG vaccine. He is interested in clinical infectious diseases, and all aspects of HIV in children and adolescents.

### Potential conflict of interest:

No Potential conflict of interest



## INVITED SPEAKER

**ANTHONY FAUCI**  
**MD**

Director of the National  
Institute of Allergy and Infec-  
tious Diseases (NIAID) at the  
U.S. National Institutes of  
Health, United States

Anthony S. Fauci is director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health, where he oversees an extensive research portfolio focused on infectious and immune-mediated diseases.

As the long-time chief of the NIAID Laboratory of Immunoregulation, Dr. Fauci has made many seminal contributions in basic and clinical research and is one of the world's most-cited biomedical scientists.

He was one of the principal architects of the President's Emergency Plan for AIDS Relief (PEPFAR), a program that has saved millions of lives throughout the developing world.

### Potential conflict of interest:



# Faculty



## ORGANIZING COMMITTEE

**PATRICIA FLYNN  
MD**

St. Jude Children's Research  
Hospital,  
United States

Pat Flynn is a Member in the Department of Infectious Diseases at SJCRH where she holds the Arthur Ashe Chair in Pediatric AIDS Research. She is also Professor of Pediatrics and Preventive Medicine at the University of Tennessee Health Science Center. She received her medical training at Louisiana State University Medical Center (1981) and completed Pediatric (1984) and Pediatric Infectious Diseases (1987) training at the University of Tennessee/St. Jude Children's Research Hospital/LeBonheur Children's Medical Center joint program.

Dr. Flynn began working in the HIV/AIDS program at St. Jude Children's Research Hospital in 1988. Over the past 30 years, she has had the opportunity to watch the dramatic reductions in the rate of mother to child HIV transmission and the introduction of active medications that extend the life of HIV-infected persons.

She has also witnessed the rising new infection rates in the adolescents through high risk behaviors. The St. Jude HIV clinic provides comprehensive care for over 300 HIV-infected infants, children, and adolescents. Dr. Flynn and the St. Jude clinic participate in the International Maternal Pediatric and Adolescent Clinical Trials Group (IMPAACT) and the Pediatric HIV/AIDS Cohort Study (PHACS).

**Potential conflict of interest:**  
Merck



## ORGANIZING COMMITTEE

**CARLO GIAQUINTO  
MD**

University of Padova,  
Italy

Carlo Giaquinto graduated in Medicine (1982) and specialised in Pediatrics (1986) at the University of Padova. He is Professor at the Department for Woman's and Child's Health of the University of Padova, Director of the Paediatric and Neonatal Infectious Disease Unit at same Department and Director of the Course in Developmental Medicine and Health Planning Sciences at the University of Padova. Prof. Giaquinto is also the President of Fondazione Penta and of Fondazione C.A.R.A.P. Onlus and Scientific Responsible and Vice President of Fondazione Moschino.

His main interest has always been the research in the field of Paediatric Infections and was founder of the European Collaborative Study on the natural history of HIV infections in childhood. He is the coordinator of several International research projects and scientific reviewer of several international journals including The Lancet, AIDS, PIDJ, HIV Medicine, Paediatrics, and Member of the Editorial Board of the research journal "Infectious Diseases" and of "Journal of Virus Eradication".

He is Author/co-author of more than 230 publications published in peer-reviewed and invited as speaker at about 600 conferences and international workshops across the world. On 26th May 2017 Carlo Giaquinto was given the European Society for Paediatric Infectious Diseases (ESPID) Bill Marshal Award.

**Potential conflict of interest:**  
Gilead, ViiV, and JnJ







## SCIENTIFIC COMMITTEE

**ALI JUDD**  
**PhD**

University College London,  
United Kingdom

Ali Judd is a Professor of Epidemiology at UCL. She started her career at what was then Charing Cross and Westminster Medical School (now Imperial College London), doing data entry for various HIV studies. She went on to be a researcher on studies of HIV and hepatitis C in drug users, and studied for an MSc and PhD in Epidemiology at the London School of Hygiene and Tropical Medicine.

She has worked in paediatric HIV and hepatitis C at the MRC Clinical Trials Unit at UCL since 2005. Over the last 15 years she has set up and now co-coordinates a network of cohort studies across Eastern and Western Europe and Thailand, addressing questions in paediatric HIV and related infections. This network is the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC), which is part of Penta. She is also a co-investigator in the International AIDS Society Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Cohort Collaboration, within which questions of global public health importance for children and young people living with HIV are addressed.

For hepatitis C, she is developing studies investigating treatment options for pregnant women with chronic HCV. Her observational studies run parallel to the paediatric and adolescent infection trials at the MRC CTU, providing a complementary approach to addressing questions of trial feasibility as well as longer term effectiveness and safety.

Ali is a member of the Scientific Committee of the International Workshop on HIV Pediatrics, and she is a trustee of the Children's HIV Association.

**Potential conflict of interest:**  
Gilead Sciences



## INVITED SPEAKER

**DAN KURITZKES**  
**MD**

Harvard Medical School /  
Brigham and Women's Hospital,  
United States

Daniel Kuritzkes is the Harriet Ryan Albee Professor of Medicine at Harvard Medical School and Chief of the Division of Infectious Diseases at Brigham and Women's Hospital in Boston, Massachusetts. He received his B.S. and M.S. degrees from Yale University and his M.D. from Harvard Medical School.

Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection. He has chaired several multicenter studies of HIV therapy and previously chaired the AIDS Clinical Trials Group. He served as a member of the NIH Office of AIDS Research Advisory Council and as a member of the U.S. Department of Health and Human Services panel on guidelines for antiretroviral therapy.

He has been a member of several editorial boards and serves as an Associate Editor of the Journal of Infectious Diseases. His research interests focus on HIV therapeutics, antiretroviral drug resistance, and HIV eradication.

**Potential conflict of interest:**  
Gilead, GlaxoSmithKline, Merck, and ViiVt



# Faculty



## SCIENTIFIC COMMITTEE

**VALÉRIANE LEROY**  
**MD**

Inserm,  
France

Valériane Leroy is the Research Director at Inserm U1027, University of Toulouse 3, Toulouse, France since 2016. She holds a MD in Epidemiology and Public Health (1993, Bordeaux University), PhD epidemiologist (1996, Bordeaux University), involved in the prevention of mother-to-child transmission research in Africa since 1995, and responsible of the pediatric research program since 2005, at Inserm U897, Bordeaux School of Public Health in Bordeaux, France from 2005 to 2015, then now in the Inserm U1027 team in Toulouse, France, as responsible of a research axis on pediatric infectious diseases in Africa. She has a specific interest in maternal and child health in low-income countries, especially in West-Africa.

To date her research has focused on HIV. Her main research interests are the burden of this infection in women and during pregnancy, mother-to-child transmission and its prevention, treatment and outcomes in HIV infected children.

She was the principal investigator of the MONOD ANRS 12206 clinical trial (ClinicalTrial.gov registry number: NCT01127204), assessing a switch from lopinavir/ritonavir-based ART to efavirenz-based ART. Currently, she is the scientific responsible of the pediatric leDEA (International epidemiological Database on AIDS) West African cohort (pWADA) since 2006, studying clinical and health resource utilization outcomes for HIV-exposed children, ART-naive children, and ART-treated children

### Potential conflict of interest:

No Potential conflict of interest



## INVITED SPEAKER

**DANIELE DE LUCA**  
**MD, PhD**

AP-HP Université Paris Saclay,  
France

Daniele De Luca is a neonatologist and pediatric intensivist, Chief of the Division of Pediatrics and Neonatal Critical Care at Paris Saclay University Hospitals.

He is the President Elect of the European Society for Pediatric and neonatal Intensive Care (ESPNIC), the largest European pediatric scientific society and Editor of the European Journal of Pediatrics.

A/Prof. De Luca's researches are mainly focused on respiratory critical care and biology of ARDS. Since the beginning of pandemics A/Prof. De Luca committed on the front line (his hospital is one of the main perinatal center in France)

and admitted several dozen of babies born to COVID19 mothers. He extensively worked on the SARS-CoV-2 infections in neonates, demonstrated the first case of transplacental SARS-CoV-2 transmission and launched the international EPICENTRE Registry of neonatal SARS-CoV-2 infections.

A/Prof. De Luca has been appointed as WHO temporary advisor for this topic.

### Potential conflict of interest:

No Potential conflict of interest





## INVITED SPEAKER

**MARY MAHY**  
**ScD, MHSc**

UNAIDS,  
Switzerland

Mary Mahy leads the epidemiology team at the Joint United Nations Programme on HIV/AIDS (UNAIDS) where she oversees the production and analysis of global data on the HIV epidemic, including supporting countries to produce annual HIV estimates. Mary also co-facilitates the HIV pediatrics estimates reference group that is linked to the UNAIDS Reference Group on Estimates, Modeling and Projections. Mary is an author on over 30 journal articles on HIV related topics, with a special focus on vertical HIV transmission and estimating child and adolescent HIV.

Prior to moving to UNAIDS headquarters in Geneva, Mary was the UNAIDS strategic information adviser in Namibia where she supported the Namibian Ministry of Health and Social Services to use data to strengthen the HIV response. Before joining UNAIDS Mary was responsible for global monitoring and evaluation of HIV at UNICEF headquarters in New York. She also worked as a research analyst for the Demographic and Health Surveys at Macro International. Mary is a demographer and received her doctorate in population dynamics from the Johns Hopkins School of Hygiene and Public Health. Her dissertation research focused on child mortality and HIV in Zimbabwe.

### Potential conflict of interest:

No Potential conflict of interest



## WORKSHOP CHAIR

**LYNNE MOFENSON**  
**MD**

Elizabeth Glaser Pediatric  
AIDS Foundation,  
United States

Lynne Mofenson is a pediatric infectious disease specialist who has spent her career doing research on prevention and treatment of pediatric and maternal HIV infection.

In 2014, she retired from the U.S. National Institutes of Health after 26 years, where she led many of the key clinical trials on prevention of mother to child transmission and pediatric and maternal treatment.

She currently serves as Senior HIV Technical Advisor to the Research Program at the Elizabeth Glaser Pediatric AIDS Foundation, where she is assisting in evaluating implementation of many of the interventions on treatment and prevention that she helped to design while at NIH.

### Potential conflict of interest:

No Potential conflict of interest



# Faculty



## INVITED SPEAKER

### FUNGAI MURAU

Independent Consultant,  
United Kingdom

Fungai Murau is a passionate researcher in the HIV field with special interest in mental health (quality of life for people living with HIV), migration and educating adolescent girls in making informed choices about their sexuality and wellbeing.

Fungai studied at the renowned Institute of Development studies with her MA (poverty and development) dissertation focusing on the mental health of undocumented women living with HIV in the UK. Fungai currently works as an independent consultant focusing on policy, advocacy and project delivery.

Fungai is affiliated with the following Advisory Boards, and committees:

- Steering Group Member: SWIFT (2015 - current)
- Mentor Mother - 4M NET (April 2016 – current)
- Community Representative: Collaborative HIV Paediatric Study (CHIPS) and CHIPS+ (September 2018 – Current)
- Implementation Group Member: Brighton & Hove Towards Zero HIV Taskforce – Stigma Implementation Group & Testing + Innovation Group (April 2018 – current)
- Board of Trustees: AMAZE (March 2008 – current)
- Board of Trustees: The Sussex Beacon (May 2019 – current)
- Board of Trustees: Beyond Stigma (February 2020 – current)

#### Potential conflict of interest:

No Potential conflict of interest



## SCIENTIFIC COMMITTEE/

### INVITED SPEAKER

### SHARON NACHMAN MD

SUNY Health Science Center  
Stony Brook,  
United States

Sharon Nachman is a scientist and pediatric clinical investigator with more than 25 years of continuous NIH support (U mechanism from the IMPAACT network) dedicated to developing and implementing clinical therapeutic trials for infants, children, adolescents and pregnant women. She has had leadership roles in over 25 clinical trials developed through the PACTG and now IMPAACT network, including 20 as either protocol chair or vice chair.

All studies have enrolled, analyzed, and published results that have changed the way we evaluate and treat HIV infected and exposed children and women worldwide. While much of her work has centered around these populations, she also developed studies helping to define the dose and PK for new antibiotics, evaluate new vaccines and understand the long term issues that develop in infants born to HIV+ women worldwide.

Professor Nachman serves as the PI and Chair of the IMPAACT Network

#### Potential conflict of interest:

No Potential conflict of interest





INVITED SPEAKER

**LUCY WANJIKU NJENGA**

Positive Young Women Voices,  
Kenya

Lucy Wanjiku Njenga is the Founding Coordinator of Sauti Skika, the first network of adolescent living with HIV in Kenya and the Founder and team leader of Positive Young Women Voices, a grassroots community-based organization that works to empower adolescent girls and young women living with or affected by HIV. She is the African Delegate in the UNAIDS NGO Delegation to the PCB.

She serves as the Alternate Board Member in the CCM representing people living with HIV a former member in Board of Directors for End AIDS Coalition and an advisory group member for GCWA. In addition, she has an active role in Athena's Initiatives #WhatWomenWant Campaign and their Young Women's Leadership Initiative wherein she supports young women and adolescent girls to expand their leadership, visibility and engagement on accountability.

**Potential conflict of interest:**

No Potential conflict of interest



INVITED SPEAKER

**REGINA OLADOKUN  
MD, MPH**

University of Ibadan,  
Nigeria

Regina Oladokun is a Professor of Paediatrics in the Department of Paediatrics, College of Medicine, University of Ibadan and Consultant Paediatrician at the University College Hospital, Ibadan, Nigeria. She is the Head of the Infectious Diseases Unit and coordinates the Paediatric HIV programme at the hospital.

She completed her residency training at the University College Hospital, Ibadan with Fellowships of the National Postgraduate Medical College and West African College of Physicians in Paediatrics. She holds a Master of Public Health (MPH) degree and obtained a fellowship in Paediatric infectious diseases at the Red Cross Children's Hospital, Cape Town as well as Master of Philosophy in Paediatric Infectious diseases from University of Cape Town.

She is currently a member of the Paediatric HIV stakeholders' forum and the TB/HIV working group of the Nigerian National programme. She is a member of trustees of African Network for Care of Children with HIV/AIDS (ANECCA). Apart from paediatric HIV research, she has also been active in the area of childhood tuberculosis and vaccine preventable diseases.

**Potential conflict of interest:**

No Potential conflict of interest



# Faculty



SCIENTIFIC COMMITTEE/  
INVITED SPEAKER

**MARTINA PENAZZATO**  
**MD, MSc, PhD**

WHO,  
Switzerland

Martina Penazzato is the paediatric lead for the HIV, Hepatitis and STIs Department of WHO Headquarter in Geneva.

In her work for the WHO, in addition to providing a major contribution to several Guidelines development processes in the areas of HIV, TB and child health, she has set up surveillance projects to assess HIVDR in HIV-infected infants and provided technical assistance to several countries in the African region.

In her current role she leads the work of WHO on paediatric treatment and care and contributes to a number of global initiatives to improve access to better medicines for children as well as pregnant and lactating women.

**Potential conflict of interest:**

No Potential conflict of interest



LOCAL CHAIR

**ANN PETRU**  
**MD**

UCSF Benioff Children's  
Hospital Oakland,  
United States

Ann Petru graduated from UCSF School of Medicine, completed Pediatric Residency and Infectious Diseases Fellowship at Children's Hospital Oakland. She is co-Director of the Division of Infectious Diseases, Director of the Pediatric HIV/AIDS Program, the Infection Control Officer and Chair of the Medical Ethics Committee. With 5 other physicians, she shares responsibility for diagnosing and caring for children with suspected and proven infectious diseases in the clinic and in the hospital.

Dr. Petru developed a busy, integrated and comprehensive center for the care of children with HIV infection since the beginning of the epidemic. The Pediatric HIV/AIDS Program has provided care for 275 HIV-infected infants, children and adolescents and over 725 HIV-exposed infants born to infected mothers. Her 40 active patients live in 17 counties in northern California, >50% are internationally adopted, and 97% currently have undetectable HIV in their blood.

She really loves her work (a mostly perfect combination of clinical care for patients, teaching of fellows, residents and medical students, and providing answers to tough clinical situations by using innovative testing mechanisms) and finds it well-balanced with other things, including family, hiking, swimming, gardening, and photography.

**Potential conflict of interest:**

No Potential conflict of interest





## SCIENTIFIC COMMITTEE

**JORGE PINTO**  
**MD, DSc**

Federal University of Minas Gerais,  
Brazil

Jorge Pinto is professor of Pediatrics and Clinical Immunology, Head of Pediatric, Adolescent and Maternal HIV/AIDS Group, Federal University of Minas Gerais in Brazil.

Dr. Pinto has been involved in the field of pediatric HIV for more than 25 years, having established one of the first and largest cohorts of children and adolescents in Brazil. He is a member of the Brazilian Scientific Advisory Committee for Pediatric, Adolescent and Perinatal AIDS, National AIDS Program since its establishment in 1995.

He is a member of the IMPAACT/NIH HIV Treatment Scientific Committee since 2006 and a member of World Health Organization Pediatric Antiretroviral Working Group since 2004.

### Potential conflict of interest:

No Potential conflict of interest



## INVITED SPEAKER

**JILLIAN PINTYE**  
**RN, MPH, PhD**

University Washington Seattle,  
United States

Jillian Pintye is a nurse-scientist and Assistant Professor at the University of Washington in Seattle, Washington, USA. Dr. Pintye's research focuses on HIV and STI prevention and treatment, particularly within maternal child health and family planning settings.

Dr. Pintye is engaged in a suite of studies related to pre-exposure prophylaxis (PrEP) for HIV prevention among pregnant and postpartum women in Kenya, including both clinical epidemiology and implementation science studies. Dr. Pintye currently leads an NIH-funded study that will systematically quantify infant pre- and postnatal PrEP exposure and assess birth, bone, growth, and neurocognitive outcomes following PrEP exposure into early childhood.

She is also a co-investigator on multiple implementation science evaluations of point-of-care STI diagnostics, PrEP provider training, and approaches to enhance the reach and quality of PrEP delivery for young women. Dr. Pintye was a Peace Corps Volunteer in Botswana, where she developed a passion for HIV prevention among women and children.

### Potential conflict of interest:

No Potential conflict of interest



# Faculty



## ORGANIZING COMMITTEE

**THANYAWEE PUTHANAKIT  
MD**

Chulalongkorn University,  
Thailand

Thanyawee Puthanakit is a pediatric infectious disease specialist at Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. She is a former trainee of the Johns Hopkins University Fogarty AIDS International Training and Research Program.

She started her clinical research in pediatric HIV/AIDS focusing on opportunistic infections and antiretroviral therapy in resource limited settings at Research Institute of Health Sciences, Chiang Mai University in 2002. She is a leader in pediatric HIV treatment and care in Asia. She leads several multicenter research projects in Thailand, Cambodia, Indonesia and also collaborates with TREAT Asia research program.

She has served on the writing committee for the WHO's pediatric HIV treatment guideline and Thai National Guideline. Her research interest in pediatric and adolescent HIV include antiretroviral therapy and elimination of perinatal HIV transmission and reduction in new cases of adolescent infection. She conducted a pilot national program using integrase inhibitors intensification regimen for late-presenting pregnant women.

**Potential conflict of interest:**  
ViiV and MSD



## SCIENTIFIC COMMITTEE

**NATELLA RAKHMANINA  
MD, PhD, FAAP, AAHIV**

Children's National Hospital /  
George Washington University,  
United States

Natella Rakhmanina is a Professor of Pediatrics at the George Washington University and serves as a Director of the HIV Program at Children's National Hospital in Washington, DC, USA. Dr. Rakhmanina obtained her MD degree at People's Friendship University in Moscow, Russia, and her PhD degree at the Erasmus University in Rotterdam, the Netherlands.

For more than 20 years she has been providing clinical care to HIV-infected infants, children and adolescents, and continues her practice treating pediatric and adolescent patients in metropolitan DC area. She is certified in HIV medicine and is a successful clinical researcher, focusing her research on the treatment and prevention of HIV in children and adolescents and serving as a principal investigator of NIH, CDC and industry funded pediatric and adolescent HIV studies.

Dr. Rakhmanina is also a Senior Technical Advisor at Elizabeth Glaser Pediatrics AIDS Foundation leading several projects on pediatric and adolescent HIV treatment in Sub-Saharan African countries. Dr. Rakhmanina is a Chair of the Committee on Pediatric AIDS at the American Academy of Pediatrics, member of the US Department of Health and Human Services Panel on the Pediatric Antiretroviral Therapy and Management Guidelines at the Office of AIDS Research Advisory Council in National Institutes of Health, member of the Pediatric Advisory Working Group at the World Health Organization, and a Regent of the Board and Chair of the Bylaws committee at the American College of Clinical Pharmacology.

**Potential conflict of interest:**  
No Potential conflict of interest







## INVITED SPEAKER

**VANESSA ROUZIER  
MD**

GHESKIO, Haiti / Weill Cornell  
Center for Global Health,  
United States

Vanessa Rouzier is the Pediatrics department chair at GHESKIO in Haiti, the largest HIV/AIDS and TB center in the Caribbean.

She is an Assistant Professor of Pediatrics in the Center for Global Health at Weill Cornell Medicine. She trained at McGill University in Canada in Pediatrics and Infectious Diseases.

In addition to providing clinical care, Vanessa conducts NIH-funded research in Maternal Child and Adolescent Health. Her interests include tuberculosis and outcomes of HIV/AIDS treatment programs, including prevention of mother to child transmission.

### Potential conflict of interest:

No Potential conflict of interest



## LOCAL CHAIR

**TED RUEL  
MD, MPH**

UCSF-Benioff Children's  
Hospital San Francisco,  
United States

Ted Ruel has devoted his career to the study of infectious disease and the improvement of child health in limited-resource settings. He completed his medical doctorate from the Yale University School of Medicine, with pediatric residency, chief residency and pediatric infectious fellowship training at the University of California, San Francisco (UCSF). He is currently an Associate Professor in the Division of Infectious Disease and Global Health at the UCSF-Benioff Children's Hospital.

Dr. Ruel performs NIH-funded clinical and translational research of HIV-infected African children in Uganda and Kenya. In the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network, he serves as vice-chair of the Treatment Scientific Committee and co-chair of "P1093," a trial examining the pharmacokinetics and efficacy of dolutegravir in children. Dr. Ruel is the principal investigator of an NIH-funded observation trial of HIV-infected infants who initiate therapy very early in life.

Dr. Ruel also serves as a vice-chair of the US Department of Health and Human Services Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Dr. Ruel's clinical practice includes caring for infants, children and young adults with HIV-infection. Dr. Ruel co-founded and remains active with the nonprofit organization, Global Strategies ([www.globalstrategies.org](http://www.globalstrategies.org)), which partners with providers at sites in Africa and India to improve maternal-child health.

### Potential conflict of interest:

No Potential conflict of interest



# Faculty



## ORGANIZING COMMITTEE

**NADIA SAM-AGUDU  
MD, CTROPMED**

Institute of Human Virology,  
Nigeria

Nadia A. Sam-Agudu is a pediatrician working for the Institute of Human Virology at the University of Maryland School of Medicine, Baltimore, USA, where she is also Associate Professor of Pediatrics in Immunology and Infectious Diseases. She is stationed full-time in Nigeria, where she serves as the Senior Technical Advisor for Pediatric and Adolescent HIV at the Institute of Human Virology Nigeria in Abuja.

Dr. Sam-Agudu graduated from the Mayo Clinic Medical School in 2002, and thereafter completed her training in Pediatrics and Pediatric Infectious Diseases at the University of Minnesota, USA. Her career focuses on the control and elimination of infectious diseases of public health importance among African children, specifically HIV, tuberculosis, and malaria.

Dr. Sam-Agudu has research experience in Ghana, Uganda and particularly in Nigeria, where she has provided technical and policy-making support for HIV programs since 2010. Her research interest is in using implementation science methods to generate evidence for sustainable HIV prevention and control among children and adolescents. To this end, she has to date served as Principal Investigator, Project Director or Mentor for projects supported by the World Health Organization, the US National Institutes of Health, the American Academy of Pediatrics, and the International AIDS Society.

**Potential conflict of interest:**  
Merck MSD



## SCIENTIFIC COMMITTEE

**GEORGE SIBERRY  
MD, MPH**

USAID,  
United States

George Siberry is a pediatric infectious disease physician who joined USAID as a medical officer in the Office of HIV/AIDS (PEPFAR) in September 2018. At USAID, he is a Deputy Principal and a senior technical advisor for adult and pediatric HIV treatment with particular focus in Kenya, Lesotho, Cameroon, Angola and South Africa. Before joining USAID, he was the director of the PEPFAR technical unit on HIV care, treatment and TB for the State Department (S/GAC), including primary responsibility for technical leadership on pediatric HIV in PEPFAR programs globally. Africa.

Prior to PEPFAR, Dr. Siberry was on full-time faculty (2003-2008) in the Department of Pediatrics and as the Director of the Harriet Lane Clinic at Johns Hopkins and medical officer position at the Pediatric Adolescent Maternal AIDS Branch of NICHD/NIH (2008-2015). He participates in WHO HIV Guidelines development and serves on the US pediatric ARV guidelines and US Perinatal Guidelines Panels. He serves as a member of the American Academy of Pediatrics (AAP) Committee on Pediatric AIDS (COPA) and as a Panel member of the FDA Antimicrobial Drug Advisory Committee.

Dr. Siberry co-authors pediatric HIV chapters in Mandell, Douglas, and Bennett's Principles & Practice of Infectious Diseases and Long, Pickering & Prober's Principles & Practice of Pediatric Infectious Diseases. He is Associate Chief Editor for the Pediatric Infectious Disease Journal for which he oversees the HIV Reports section. He provided care to children and youth with HIV infection at the Johns Hopkins Hospital for over 20 years (until 2018). He joined the Yale School of Medicine as a part-time faculty member in the Department of Pediatrics in 2019.

**Potential conflict of interest:**  
No Potential conflict of interest





## SCIENTIFIC COMMITTEE

**LYNDA STRANIX-CHIBANDA,**  
**MBC<sub>H</sub>B, MMed**

University of Zimbabwe,  
Zimbabwe

Lynda Stranix-Chibanda is a Zimbabwean researcher with 20 years of clinical trial experience and advocacy for HIV prevention.

A Paediatrician by training, Lynda lectures at the University of Zimbabwe and mentors postgraduate students. She is the Site Leader for Seke North Clinical Research Site in Chitungwiza, Zimbabwe directing NIH-funded clinical trials related to the prevention and treatment of HIV in women, adolescents and children.

Of relevance to this workshop, Lynda participated in early trials that developed the local approach for testing and counselling women for HIV in pregnancy and the dosing regimen for infant Nevirapine prophylaxis used to prevent vertical transmission during breastfeeding.

She has worked at primary care level to deliver HIV services to women and children, providing technical assistance to the national EMTCT programme and contributing to policy development for pre-exposure prophylaxis use.

### Potential conflict of interest:

No Potential conflict of interest



## ORGANIZING COMMITTEE

**GARETH TUDOR-WILLIAMS**  
**MD**

Imperial College London,  
United Kingdom

Gareth Tudor-Williams is a Professor of Paediatric Infectious Diseases at Imperial College London, and Consultant in Paediatric Infectious Diseases at Imperial College Healthcare NHS Trust, St. Mary's Hospital, London.

His interest in paediatric infectious diseases was sparked by two years of working in the Himalayas for Save the Children Fund UK. He has specialised in HIV infection in children since 1989, as a Fellow at Duke University, N. Carolina (with Prof. Cathy Wilfert), and as a Visiting Scientist / Attending Physician at the National Institutes of Health, Bethesda, MD (with Prof. Phil Pizzo).

Since 1994, he has helped run a multi-disciplinary service for HIV infected children, young people and their families at St. Mary's Hospital, London. He was the founding Chair of the Children's HIV Association of the UK and Ireland (CHIVA). He has been involved in international Phase II and III trials relating to paediatric blood-borne virus infections for 30 years.

### Potential conflict of interest:

No Potential conflict of interest

+



# Faculty



## SCIENTIFIC COMMITTEE

**RACHEL VREEMAN  
MD, MS**

Icahn School of Medicine at  
Mount Sinai,  
United States

Dr. Vreeman is a pediatrician and researcher who specializes in the improving care for children and adolescents living with HIV in resource-limited settings. She is the Vice Chair for Research at the Icahn School of Medicine at Mount Sinai in the Department of Health System Design and Global Health. She is also the Director of the Sinai Global Sites Network for the Arnhold Institute for Global Health at Mount Sinai. Dr. Vreeman chairs the Pediatric Working Group for the Global IeDEA (International Epidemiologic Databases Evaluating AIDS) consortium, a cohort with patient data for more than one million people living with HIV worldwide and funded by the National Institutes of Health.

Over the last decade, Dr. Vreeman's research has focused on supporting children and adolescents' adherence to HIV therapy, disclosure of HIV status, the durability of antiretroviral therapy regimens among children, and mental health and stigma challenges for children and adolescents in sub-Saharan Africa. Much of her research takes place with the AMPATH program in Kenya, an academic care system that treats more than 15,000 children and adolescents living with HIV.

### Potential conflict of interest:

No Potential conflict of interest



## INVITED SPEAKER

**ELIZABETH WHITTAKER  
PhD, DTM&H, MRCPCH**

Imperial College London,  
United Kingdom

Elizabeth Whittaker graduated from Trinity College Dublin, Ireland and following clinical experience in Dublin and Brisbane, Australia, moved to London. Here she trained as a paediatrician and was successfully awarded an academic clinical fellowship in paediatric infectious diseases in 2006.

Dr Whittaker completed her Wellcome Trust funded PhD project 'Immune responses to mycobacteria; the role of age and disease severity' in 2014, based between Imperial College London and the University of Cape Town in South Africa. She completed her paediatric training in 2016, combining clinical and research experience as an NIHR-funded academic clinical lecturer.

Dr Whittaker is the paediatric specialty co-lead for the North West London Clinical Research Network. She is the Convenor of the British Paediatric Allergy, Infection and Immunity Group (BPAIIG) and on the steering committee of the British Association of Paediatric TB (BAPT). She is the co-lead for high consequence infectious diseases (HCID) in children at Imperial and is on the RCPCH expert advisory group for COVID 19. With the ID research team at Imperial College, she described the emerging disease PIMS-TS and works closely with national and international groups to determine a case definition, best treatment plan and follow up.

Dr Whittaker is currently is the quality adviser to the paediatric allergy, immunology and infectious diseases CSAC committee at the Royal College of Paediatrics and Child Health.

### Potential conflict of interest:

No Potential conflict of interest



## CORPORATE SUPPORT

### PLATINUM LEVEL

---




### GOLD LEVEL

---



### SILVER

---



# Acknowledgments

## ENDORSED BY



**Elizabeth Glaser  
Pediatric AIDS Foundation**  
Fighting for an AIDS-free generation

